Navigation Links
KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
Date:2/23/2009

DEERFIELD, Ill., Feb. 23 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that KAPIDEX(TM) (dexlansoprazole) delayed release capsules are now available in pharmacies across the U.S. KAPIDEX, available in 30 mg and 60 mg doses, was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

KAPIDEX is the first proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication. PPIs work by turning off many of the acid pumps in the stomach. KAPIDEX contains two types of enteric-coated granules resulting in a concentration-time profile with two distinct peaks: the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. In addition, KAPIDEX can be taken regardless of when food is consumed.

GERD is a chronic condition commonly known as acid reflux disease. GERD affects nearly 19 million Americans and is often characterized by frequent and persistent heartburn that occurs two or more days a week despite treatment and diet changes. GERD can affect both men and women, and symptoms are often triggered by certain foods, stress or pressure on the stomach.

About KAPIDEX (dexlansoprazole) delayed release capsules

KAPIDEX (dexlansoprazole) delayed release capsules, previously known by the development code TAK-390MR, is a proton pump inhibitor (PPI), which decreases acid production by turning off many of the acid pumps in the stomach, thus helping to protect the esophagus from acidic reflux so that esophageal inflammation can heal. KAPIDEX combines an enantiomer of lansoprazole with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication. KAPIDEX, taken once-daily, is approved for the healing of all grades of erosive esophagitis (EE) for up to eight weeks, maintaining healing of EE for up to six months, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Important Safety Information

KAPIDEX is contraindicated in patients with known hypersensitivity to any component of the formulation. Symptomatic response with KAPIDEX does not preclude the presence of gastric malignancy. The most commonly reported treatment-emergent adverse reactions (greater than or equal to 2%): diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence. KAPIDEX should not be co-administered with atazanavir. KAPIDEX may interfere with the absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time.

Please see the complete prescribing information and visit the KAPIDEX Web site at www.kapidex.com.

Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, oncology, gastroenterology, neurology, rheumatology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. KV Pharmaceuticals Launch of Gestiva(TM) Delayed
2. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
3. SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed
4. Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
5. Heart Attack Care Often Delayed for the Poor
6. Womens Alcohol Use Tied to Delayed Childbearing
7. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
8. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
9. Watson Launches Omeprazole Delayed-Release Capsules, 40MG
10. Delayed Sleep Pattern Tied to Irregular Menstrual Cycles
11. Teens Sleep Longer With Delayed School Starts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... Genes ... for medications in select Florida and Texas doctors' offices and clinics. This breakthrough ... application of genetic testing recognizes the role genes play in determining an individual's ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman and ... in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency dental ... dentist fit into their patients’ busy lifestyles. Dental365 also gladly work with most ...
(Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ways ... alarm system installed. But unless there is a working deadbolt lock that is used ... Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use force ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... what is needed and will ultimately do significant harm to people with all ... everyone. , "While it leaves in place the Affordable Care Act (ACA) ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... (BCRA), their proposed healthcare bill to repeal and replace the Affordable Care Act ... bill would make significant cuts to Medicaid, a public health insurance program for ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
Breaking Medicine Technology: